



THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JUL 17 2003
TECH CENTER 1600/200

Applicants: Scott F. Sneddon, John L. Kane, Bradford H. Hirth, Fred V. Voth, Shuang Qiao and Sharon R. Nahill

Application No.: 09/852,965 Group: 1624

Filed: May 10, 2001 Examiner: V. Balasubramanian

Confirmation No.: 4903

For: Modulators of TNF- α Signaling


CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2227, Arlington, VA 22202-2231-1450	
on 7.9.03	Signature Sandra Brigham
Date	Signature
SANDRA BRIGHAM	
Typed or printed name of person signing certificate	

DECLARATION OF SCOTT F. SNEDDON, PH.D. UNDER 37 C.F.R. § 1.132

Sir:

I, Scott F. Sneddon of 38 Washington Square South, Salem Massachusetts, 01970, hereby declare and state:

1. I am a co-inventor of the subject matter described and claimed in U.S. Serial No. 09/852,965, filed May 10, 2001 and entitled "Modulators of TNF- α Signalling". U.S. Serial No. 09/852,965 is hereinafter referred to as the "965 Application". I have read and am thoroughly familiar with the invention claimed therein.
2. Compounds 1-4, shown below in the Table, were prepared under my supervision according to Schemes VI-VIII, shown on pages 29-33 of the subject application:




The Table


Compound	R ₁₀	IC ₅₀ (μM)
Compound 1	-H	>30
Compound 2	-CH ₃	>30
Compound 3	-CH(CH ₃) ₂	>30
Compound 4	-C(CH ₃) ₃	>30

3. Compounds 1-4 were tested in the TNF- α induced apoptosis assay described on pages 70-71 of the subject application and the IC₅₀s were determined. The results are shown in the Table above. The IC₅₀ is the concentration at which the compound tested inhibits 50% of the TNF induced response apoptosis of L929 cells in the assay. As can be seen from these datas, all of the compounds had an IC₅₀ greater than 30 micromolar, indicating that the compounds were largely ineffective in inhibiting TNF- α induced apoptosis.

4. I further declare that all statements herein of my own knowledge are true and that all statements made on information in belief are believed to be true; and further that the statements are made with the knowledge that willful false statements of the like so made are punishable by fine or imprisonment or both Under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereof.



Scott F. Sneddon, Ph.D.



Dated